Herein, we showed that miR-181a inhibition enhanced the growth of NBM CD34+ cells and that this effect was enhanced by BCR-ABL, which strongly suggested the tumor-suppressor role of miR-181a in BCR-ABL+ leukemic cells. This evidence concerns the gene BCR and neoplasm.